Bio

Mr. Fréchette joined RoundTable in January 2016 in connection with the launch of Fund IV as a Senior Operating Partner and member of the Management Committee, responsible for identifying new investment opportunities and overseeing the operational performance of RoundTable’s Fund IV pharmaceutical related platforms. Mr. Fréchette currently serves as non-executive Chairman of the Boards of Renaissance Pharmaceuticals, Revision Skincare/Goodier Cosmetics, as well as Deerland Probiotics & Enzymes. He also serves on the board of Symmetry Surgical. He joined RoundTable’s Renaissance platform at its inception as Chief Executive Officer in 2010 and continued to lead that business during a transition period until the sale of its Topical Division in May 2016. Previously, Mr. Fréchette was Chief Executive Officer of RoundTable’s Sabex platform through its sale to Sandoz Canada, Inc. in 2004. He continued on as President and Chief Executive Officer of Sandoz Canada, Inc. where he led the global generic injectable business until 2010. Mr. Fréchette has more than 35 years of healthcare industry experience in North America and Europe, including 20 years with Baxter.